Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

RNA Interference with Chemically Modified Sirna.

Chemically Modified Sirnas and Their Conjugates

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Recent Progress on Sirna Conjugates

Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of Sirnas

Synthetic SiRNA Delivery: Progress and Prospects

Optimization in Chemical Modification of Single-Stranded Sirna Encapsulated by Neutral Cytidinyl/Cationic Lipids

Synthesis And Properties Of Novel L-Isonucleoside Modified Oligonucleotides And Sirnas

Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability

Research Progress on Sirna Delivery with Nonviral Carriers

Improving the Potency Prediction for Chemically Modified siRNAs through Insights from Molecular Modeling Focused on Individual Sequence Positions

Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs

Chemical Synthesis of Modified RNA

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

RNAi-based drug design: considerations and future directions

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Comprehensive Analysis of Sequence-Specific Stability of Sirna

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Asymmetric Sirna: New Strategy to Improve Specificity and Reduce Off-Target Gene Expression.

RNA Interference and Potential Applications

siRNAs as potential drugs.